Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15375405 | 0.88 | EPHX1 (0.44) | ACEEPHX1CYP1A2TAAR1SIGMAR1 | |
| SCHEMBL18435256 | 0.81 | SIGMAR1 (0.46) | CYP1A2TRPA1TAAR1SIGMAR1SLC18A2 | |
| SCHEMBL19559843 | 0.77 | SIGMAR1 (0.53) | EPHX1TAAR1SIGMAR1SLC18A2MEN1 | |
| SCHEMBL3554246 | 0.76 | CTRB1 (0.50) | ACECYP1A2TAAR1CAPN1NPC1 | |
| SCHEMBL7626858 | 0.76 | CTRB1 (0.50) | ACECYP1A2TAAR1CAPN1NPC1 | |
| SCHEMBL7789516 | 0.76 | SIGMAR1 (0.53) | EPHX1TAAR1SIGMAR1SLC18A2MEN1 | |
| SCHEMBL6926559 | 0.75 | SIGMAR1 (0.36) | ACEEPHX1TAAR1SIGMAR1MEN1 | |
| SCHEMBL7789508 | 0.74 | EPHX1 (0.61) | ACEEPHX1CYP1A2TAAR1SIGMAR1 | |
| SCHEMBL7789504 | 0.74 | EPHX1 (0.61) | ACEEPHX1CYP1A2TAAR1SIGMAR1 | |
| SCHEMBL1444462 | 0.74 | CYP1A2 (0.45) | EPHX1CYP1A2TRPA1TAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102206-B1 | SALTS OF 3-(3-AMINO-2-(R)-HYDROXY-PROPYL)-1-(4-FLUORO-PHENYL)-8-(8-METHYL-NAPHTHALEN-1-YLMETHYL)-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-8703948-B2 | Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-22 | — | — | US | disclosed |
| CN-102600116-A | Application of teprenone in resisting neurotoxicity caused by methamphetamine | UNIV KUNMING SCIENCE & TECHNOLOGY | 2012-07-25 | — | — | CN | disclosed |
| EP-2102206-A1 | SALTS OF 3-(3-AMINO-2-(R)-HYDROXY-PROPYL)-1-(4-FLUORO-PHENYL)-8-(8-METHYL-NAPHTHALEN-1-YLMETHYL)-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-23 | — | — | EP | disclosed |
| EP-1765324-A4 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | NATREON INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080176882-A1 | SALTS OF 3-(3-AMINO-2-(R)-HYDROXY-PROPYL)-1-(4-FLUORO-PHENYL)-8-(8-METHYL-NAPHTHALEN-1-YLMETHYL)-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008067167-A1 | SALTS OF 3-(3-AMINO-2-(R)-HYDROXY-PROPYL)-1-(4-FLUORO-PHENYL)-8-(8-METHYL-NAPHTHALEN-1-YLMETHYL)-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| EP-1765324-A2 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | Natreon Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006007310-A2 | COMPOSITIONS OF STABLE BIOACTIVE METABOLITES OF DOCOSAHEXAENOIC (DHA) AND EICOSAPENTAENOIC (EPA) ACIDS | NATREON INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | NATREON INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176882-A1 | SALTS OF 3-(3-AMINO-2-(R)-HYDROXY-PROPYL)-1-(4-FLUORO-PHENYL)-8-(8-METHYL-NAPHTHALEN-1-YLMETHYL)-1,3,8-TRIAZA-SPIRO[4.5]DECAN-4-ONE | HTR1A, NR3C1, HTR4 | ACE 4165/4885EPHX1 1846/4885CYP1A2 474/4885 |
| US-20050282781-A1 | Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids | ALOX15, ALOX12, BDKRB2 | ACE 2718/4885EPHX1 145/4885CYP1A2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.